{"protocolSection":{"identificationModule":{"nctId":"NCT04760652","orgStudyIdInfo":{"id":"2000029473"},"secondaryIdInfos":[{"id":"1265736169","type":"OTHER","domain":"National Provider Identifier (NPI) #"},{"id":"1R01MH125205-01","type":"NIH","link":"https://reporter.nih.gov/quickSearch/1R01MH125205-01"}],"organization":{"fullName":"Yale University","class":"OTHER"},"briefTitle":"Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","officialTitle":"CBT-ENDURE: Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","acronym":"ENDURE"},"statusModule":{"statusVerifiedDate":"2026-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-03-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2025-06-30","type":"ACTUAL"},"studyFirstSubmitDate":"2021-02-04","studyFirstSubmitQcDate":"2021-02-15","studyFirstPostDateStruct":{"date":"2021-02-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-07-15","resultsFirstSubmitQcDate":"2026-08-20","resultsFirstPostDateStruct":{"date":"2026-09-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-08-20","lastUpdatePostDateStruct":{"date":"2026-09-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Yale University","class":"OTHER"},"collaborators":[{"name":"National Institute of Mental Health (NIMH)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI). Subjects will be randomized (1:1) to receive CBT (computer-assisted) or TAU alone following esketamine.","detailedDescription":"Specific Aim 1: To determine the feasibility and safety of performing a larger study examining the effectiveness and mechanism of action of CBT to improve the longer-term outcomes following esketamine treatment in patients hospitalized for suicidal ideation or suicide attempt.\n\nSpecific Aim 2: To evaluate the appropriateness and utility of the proposed tests of cognitive control measures in exploring the mechanisms underlying the effects on depression of esketamine and the combination of esketamine+CBT.\n\nSpecific Aim 3: To examine the efficacy of esketamine+CBT combination compared to esketamine+TAU in reducing suicidal ideation.\n\nIn August 2022, the targeted enrollment was expanded to include outpatient participants, the anticipated enrollment was increased from 60 to 100 participants as a result."},"conditionsModule":{"conditions":["Depression and Suicide"],"keywords":["Depression","Suicide"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Esketamine:All participants will receive esketamine for MDSI (Major depression with suicidal ideation) as part of their standard care. The protocol will adhere to the FDA label for this product and the FDA-registered trials.\n\nCBT:Half of participants will be randomized to the CBT intervention, which will consist of an in-person and computer-based component (based on Good Days Ahead). In total, this will consist of 20 total sessions given over 16 weeks (the first 4 weeks of CBT will have sessions twice weekly; thereafter sessions will be held weekly).\n\nTAU only:Participants not randomized to CBT will undergo treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which may include physician visits and psychotherapy (except for formal CBT).","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"Rater blinded","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":93,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CBT Cognitive Behavioral Therapy","type":"ACTIVE_COMPARATOR","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.","interventionNames":["Behavioral: Cognitive Behavioral Therapy CBT"]},{"label":"TAU Treatment As Usual","type":"OTHER","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).","interventionNames":["Other: TAU"]}],"interventions":[{"type":"BEHAVIORAL","name":"Cognitive Behavioral Therapy CBT","description":"CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT","armGroupLabels":["CBT Cognitive Behavioral Therapy"]},{"type":"OTHER","name":"TAU","description":"Treatment as usual- can vary.","armGroupLabels":["TAU Treatment As Usual"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To Determine the Feasibility of Performing a Larger Study With Similar Design by Measuring of Recruitment Rates.","description":"Feasibility will be evaluated by measures of recruitment rates measured by attaining 80% of recruitment target will be considered feasible. Presented are those that were consented and then randomized.","timeFrame":"Recruitment rates will be assessed at 18 months."},{"measure":"To Determine the Feasibility of Performing a Larger Study With Similar Design by Measuring Attrition.","description":"Feasibility will be evaluated by measures of attrition rates by attaining 80% of retention will of 70% of participants will be considered feasible.","timeFrame":"Attrition will be assessed at 18 months."},{"measure":"Reasons for Discontinuation","description":"Feasibility will be evaluated by measures of reasons for discontinuation regardless of clinical state, to Week 18 or later will be considered feasible.","timeFrame":"Discontinuation will be assessed at 18 months."},{"measure":"To Determine the Safety of Performing a Larger Study With Similar Design.","description":"Safety will be evaluated by measures of the number by type of protocol deviations.","timeFrame":"Safety will be assessed at 18 months."},{"measure":"Evaluate the Appropriateness of the Proposed Tests of Cognitive Control Measures in Exploring the Mechanisms of Change.","description":"Appropriateness will be evaluated by the proportion of patients who are able to complete the cognitive control assessments. As this is a feasibility study, we do not have pre-specified quantitative cutoffs.","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Efficacy of Esketamine/CBT Combination Compared to Esketamine/TAU in Reducing the Risk of Suicide.","description":"Efficacy will be measured by the response to the MADRS (Montgomery-Asberg Depression Rating Scale). The MADRS is a 10 question assessments conducted in an interview setting.\n\nEach item is scored from 0 to 6. Total score ranges from 0 to 60. Higher scores indicate more severe depressive symptoms.","timeFrame":"Measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary observation will be the last observation carried forward per protocol at Week 18."}],"otherOutcomes":[{"measure":"To Evaluate the Depression Assessments BDI-II (Beck Depression Inventory).","description":"The BDI-II range of values is 0-42 and the clinical interpretation are indicated with higher scores indicating greater severity of illness.","timeFrame":"BDI-II will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18."},{"measure":"To Evaluate the Depression Assessments CGI (Clinical Global Impression for Severity of Suicidality).","description":"The CGI range of values is 1-5 and the clinical interpretation is indicated with higher scores indicating greater severity of illness.","timeFrame":"CGI will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18."},{"measure":"To Evaluate the Suicide Ideation Assessments CSSRS (COLUMBIA-SUICIDE SEVERITY RATING SCALE).","description":"The CSSRS range of values 0-5 and the clinical interpretation is indicated with higher score indicating greater severity.","timeFrame":"The CSSRS will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18."},{"measure":"To Evaluate the BSI (Beck Scale for Suicidal Ideation).","description":"The BSI range of values 0-63 and the clinical interpretation is indicated with higher scores indicating greater severity of illness.","timeFrame":"The BSI will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18."},{"measure":"To Evaluate the RRS (Ruminative Responses Scale).","description":"RRS range of values is 22-88, with higher scores indicating greater severity.","timeFrame":"We will compare at Week 18 using last observation carried forward per protocol."},{"measure":"To Evaluate the SoCT (Skills of Cognitive Therapy.","description":"SoCT range of values is 8-40, with higher scores indicating greater mastery of CBT.","timeFrame":"We will compare at Week 18 using last observation carried forward per protocol."},{"measure":"To Evaluate CTAS (Computer-Assisted Cognitive-Behavior Therapy for Depression).","description":"CTAS range of values is 0-40, with higher scores indicating greater knowledge of CBT.","timeFrame":"We will compare at Week 18 using last observation carried forward per protocol."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants are eligible for the study if they meet all the following criteria:\n\n  1. Written informed consent before any study procedures are performed\n  2. Meeting criteria for inpatient admission for suicidal ideation or attempt at one of the study sites\n  3. Recommended by a physician for esketamine treatment\n  4. Males or females ages 18 through 65 years of age\n  5. Diagnosis of major depressive disorder as confirmed by the MINI (inpatient) or the HAM-D-17 (outpatient)\n  6. Willing to adhere to a reliable form of contraception throughout the trial and for one month following completion of the trial (for subjects who are sexually active)\n  7. In the opinion of the investigator, the patient is willing and able to comply with scheduled visits, treatment plan, and other trial procedures for the duration of the study\n\nExclusion Criteria:\n\n* Participants are excluded if they meet any of the following criteria:\n\n  1. Active substance use disorder (except tobacco) within 6 months of screening date\n  2. Meets DSM-5 criteria for bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, or pervasive development disorder\n  3. Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to meaningfully engage in CBT (per investigator judgment)\n  4. Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study.\n  5. Current or planned participation in a formal CBT program defined by the following characteristics, each session has an agenda, a homework assignment is given at each session, and the homework assignment from the previous session is reviewed at the following appointment.\n  6. Previous Esketamine or ketamine treatment that did not produce a clinical response as outlined below.\n\n     * 6 treatments with Esketamine at a dose of 56 mg or more with no clinical response\n     * 6 treatments of IV ketamine at a dose between 0.4 mg/kg and 0.7mg /kg with no clinical response Patients must not have received Esketamine or ketamine treatment within the past 12 weeks of time of enrollment.\n  7. The patient is pregnant or breastfeeding\n  8. Unable to give informed consent\n  9. Was previously enrolled/randomized into the trial\n  10. Patients who have a contraindication to receiving Esketamine including any of the following:\n\n      * aneurysmal vascular disease\n      * arteriovenous malformation\n      * history of intracerebral hemorrhage\n      * hypersensitivity to esketamine or ketamine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Samuel T Wilkinson, MD","affiliation":"Yale University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"UAB Medicine | Heersink School of Medicine","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Yale University","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Emory University","city":"Atlanta","state":"Georgia","zip":"30329","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}}]},"referencesModule":{"references":[{"pmid":"42095692","type":"DERIVED","citation":"Wilkinson ST, Kitay BM, Macaluso M, Santucci MC, Kumpf K, Voghell C, Astorino L, Hershenberg R, Martinez-Kaigi V, Nowell T, Thase ME, Sanacora G, Rhee TG. Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial. J Clin Psychiatry. 2026 May 4;87(2):25m16285. doi: 10.4088/JCP.25m16285."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"FG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"30"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Patient discontinued from treatment protocol; assessments continue to be collected","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"No description","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"BG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"93"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.6","lowerLimit":"20.0","upperLimit":"63.8"},{"groupId":"BG001","value":"34.9","lowerLimit":"18.7","upperLimit":"61.5"},{"groupId":"BG002","value":"35.8","lowerLimit":"18.7","upperLimit":"63.8"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Sex/Gender","categories":[{"title":"Male","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"62"}]},{"title":"Female","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"27"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"82"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"80"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"93"}]}]}]},{"title":"Marital Status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Civil union/cohabitating","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]},{"title":"Divorced","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]},{"title":"Married","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"35"}]},{"title":"Never married","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"39"}]}]}]},{"title":"Education","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"College graduate (Bachelor's)","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"29"}]},{"title":"High school graduate","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]},{"title":"Master's degree","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]},{"title":"Professional or graduate degree (beyond Master's degree)","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]},{"title":"Some college","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"29"}]},{"title":"Some high school","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"To Determine the Feasibility of Performing a Larger Study With Similar Design by Measuring of Recruitment Rates.","description":"Feasibility will be evaluated by measures of recruitment rates measured by attaining 80% of recruitment target will be considered feasible. Presented are those that were consented and then randomized.","populationDescription":"Those consented and randomized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Recruitment rates will be assessed at 18 months.","groups":[{"id":"OG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"OG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}]}]},{"type":"PRIMARY","title":"To Determine the Feasibility of Performing a Larger Study With Similar Design by Measuring Attrition.","description":"Feasibility will be evaluated by measures of attrition rates by attaining 80% of retention will of 70% of participants will be considered feasible.","populationDescription":"Those consented and randomized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Attrition will be assessed at 18 months.","groups":[{"id":"OG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"OG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}]}]}]},{"type":"PRIMARY","title":"Reasons for Discontinuation","description":"Feasibility will be evaluated by measures of reasons for discontinuation regardless of clinical state, to Week 18 or later will be considered feasible.","populationDescription":"Those consented and randomized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Discontinuation will be assessed at 18 months.","groups":[{"id":"OG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"OG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"classes":[{"categories":[{"title":"Participant Withdrew","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]},{"title":"Terminated by Principle Investigator","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]},{"title":"Lost to Follow-Up","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]},{"title":"Other","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]},{"title":"Patient discontinued from treatment protocol; assessments continue to be collected","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]},{"title":"Completed Study","measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}]}]}]},{"type":"PRIMARY","title":"To Determine the Safety of Performing a Larger Study With Similar Design.","description":"Safety will be evaluated by measures of the number by type of protocol deviations.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"protocol deviations","timeFrame":"Safety will be assessed at 18 months.","groups":[{"id":"OG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"OG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"PRIMARY","title":"Evaluate the Appropriateness of the Proposed Tests of Cognitive Control Measures in Exploring the Mechanisms of Change.","description":"Appropriateness will be evaluated by the proportion of patients who are able to complete the cognitive control assessments. As this is a feasibility study, we do not have pre-specified quantitative cutoffs.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"6 months","groups":[{"id":"OG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"OG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"33"}]}],"classes":[{"title":"3PRLT","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"}]}]},{"title":"Stroop","categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"29"}]}]},{"title":"N-Back","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"}]}]}]},{"type":"SECONDARY","title":"Efficacy of Esketamine/CBT Combination Compared to Esketamine/TAU in Reducing the Risk of Suicide.","description":"Efficacy will be measured by the response to the MADRS (Montgomery-Asberg Depression Rating Scale). The MADRS is a 10 question assessments conducted in an interview setting.\n\nEach item is scored from 0 to 6. Total score ranges from 0 to 60. Higher scores indicate more severe depressive symptoms.","populationDescription":"Data are presented at each follow up with the number of participants completing the instrument.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"score on a scale","timeFrame":"Measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary observation will be the last observation carried forward per protocol at Week 18.","groups":[{"id":"OG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT"},{"id":"OG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39","lowerLimit":"23","upperLimit":"56"},{"groupId":"OG001","value":"39","lowerLimit":"16","upperLimit":"53"}]}]},{"title":"Study Day 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26","lowerLimit":"1","upperLimit":"43"},{"groupId":"OG001","value":"19.5","lowerLimit":"2","upperLimit":"48"}]}]},{"title":"Study Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27","lowerLimit":"1","upperLimit":"47"},{"groupId":"OG001","value":"25","lowerLimit":"1","upperLimit":"51"}]}]},{"title":"Study Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27","lowerLimit":"2","upperLimit":"53"},{"groupId":"OG001","value":"25","lowerLimit":"2","upperLimit":"53"}]}]},{"title":"Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","lowerLimit":"2","upperLimit":"49"},{"groupId":"OG001","value":"21.5","lowerLimit":"0","upperLimit":"48"}]}]},{"title":"Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23","lowerLimit":"1","upperLimit":"47"},{"groupId":"OG001","value":"21","lowerLimit":"0","upperLimit":"49"}]}]},{"title":"Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24","lowerLimit":"0","upperLimit":"47"},{"groupId":"OG001","value":"21","lowerLimit":"3","upperLimit":"41"}]}]},{"title":"Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","lowerLimit":"0","upperLimit":"48"},{"groupId":"OG001","value":"20","lowerLimit":"1","upperLimit":"46"}]}]},{"title":"Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19","lowerLimit":"0","upperLimit":"47"},{"groupId":"OG001","value":"17.5","lowerLimit":"0","upperLimit":"44"}]}]},{"title":"Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20","lowerLimit":"0","upperLimit":"49"},{"groupId":"OG001","value":"18","lowerLimit":"0","upperLimit":"43"}]}]},{"title":"Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17","lowerLimit":"0","upperLimit":"45"},{"groupId":"OG001","value":"18","lowerLimit":"0","upperLimit":"43"}]}]},{"title":"Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14","lowerLimit":"0","upperLimit":"40"},{"groupId":"OG001","value":"13","lowerLimit":"0","upperLimit":"48"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the Depression Assessments BDI-II (Beck Depression Inventory).","description":"The BDI-II range of values is 0-42 and the clinical interpretation are indicated with higher scores indicating greater severity of illness.","reportingStatus":"NOT_POSTED","timeFrame":"BDI-II will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18.","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the Depression Assessments CGI (Clinical Global Impression for Severity of Suicidality).","description":"The CGI range of values is 1-5 and the clinical interpretation is indicated with higher scores indicating greater severity of illness.","reportingStatus":"NOT_POSTED","timeFrame":"CGI will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18.","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the Suicide Ideation Assessments CSSRS (COLUMBIA-SUICIDE SEVERITY RATING SCALE).","description":"The CSSRS range of values 0-5 and the clinical interpretation is indicated with higher score indicating greater severity.","reportingStatus":"NOT_POSTED","timeFrame":"The CSSRS will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18.","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the BSI (Beck Scale for Suicidal Ideation).","description":"The BSI range of values 0-63 and the clinical interpretation is indicated with higher scores indicating greater severity of illness.","reportingStatus":"NOT_POSTED","timeFrame":"The BSI will be measured at Baseline, study day 2, study day 15, study day 30, weeks 7 - 17, week 18, week 26. The primary assessment of this outcome will be at Week 18.","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the RRS (Ruminative Responses Scale).","description":"RRS range of values is 22-88, with higher scores indicating greater severity.","reportingStatus":"NOT_POSTED","timeFrame":"We will compare at Week 18 using last observation carried forward per protocol.","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the SoCT (Skills of Cognitive Therapy.","description":"SoCT range of values is 8-40, with higher scores indicating greater mastery of CBT.","reportingStatus":"NOT_POSTED","timeFrame":"We will compare at Week 18 using last observation carried forward per protocol.","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate CTAS (Computer-Assisted Cognitive-Behavior Therapy for Depression).","description":"CTAS range of values is 0-40, with higher scores indicating greater knowledge of CBT.","reportingStatus":"NOT_POSTED","timeFrame":"We will compare at Week 18 using last observation carried forward per protocol.","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 18 months","eventGroups":[{"id":"EG000","title":"CBT Cognitive Behavioral Therapy","description":"Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.\n\nCognitive Behavioral Therapy CBT: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT","deathsNumAffected":1,"deathsNumAtRisk":47,"seriousNumAffected":13,"seriousNumAtRisk":47,"otherNumAffected":41,"otherNumAtRisk":47},{"id":"EG001","title":"TAU Treatment As Usual","description":"Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).\n\nTAU: Treatment as usual- can vary.","deathsNumAffected":0,"deathsNumAtRisk":46,"seriousNumAffected":9,"seriousNumAtRisk":46,"otherNumAffected":39,"otherNumAtRisk":46}],"seriousEvents":[{"term":"DEATH","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"DEPRESSION","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"DRUG DEPENDENCE","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"HOSPITALIZATION","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"INFECTION","organSystem":"INFECTIONS AND INFESTATIONS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"INJURY","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"RESPIRATORY DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"SELF-INJURIOUS BEHAVIOR","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"SUICIDAL IDEATION","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47},{"groupId":"EG001","numAffected":4,"numAtRisk":46}]},{"term":"SUICIDE ATTEMPT","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47},{"groupId":"EG001","numAffected":2,"numAtRisk":46}]},{"term":"WORSENING SI LEADING TO HOSPITALIZATION","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]}],"otherEvents":[{"term":"ANXIETY","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47},{"groupId":"EG001","numAffected":4,"numAtRisk":46}]},{"term":"CARDIOVASCULAR DISORDER","organSystem":"CARDIAC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"CONSTIPATION","organSystem":"GASTROINTESTINAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"DEPRESSION","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"DISSOCIATION","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47},{"groupId":"EG001","numAffected":4,"numAtRisk":46}]},{"term":"DIZZINESS","organSystem":"NERVOUS SYSTEM DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47},{"groupId":"EG001","numAffected":2,"numAtRisk":46}]},{"term":"DRY MOUTH","organSystem":"GASTROINTESTINAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":47},{"groupId":"EG001","numAffected":0,"numAtRisk":46}]},{"term":"DYSPHORIA","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"FATIGUE","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"GASTRITIS","organSystem":"GASTROINTESTINAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"GENERALIZED PAIN","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"HEADACHE","organSystem":"NERVOUS SYSTEM DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":47},{"groupId":"EG001","numAffected":18,"numAtRisk":46}]},{"term":"INFECTION","organSystem":"INFECTIONS AND INFESTATIONS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":47},{"groupId":"EG001","numAffected":11,"numAtRisk":46}]},{"term":"MUSCULOSKELETAL PAIN","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":47},{"groupId":"EG001","numAffected":4,"numAtRisk":46}]},{"term":"MYALGIA","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"NAUSEA","organSystem":"GASTROINTESTINAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":47},{"groupId":"EG001","numAffected":14,"numAtRisk":46}]},{"term":"RESPIRATORY DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"SELF-INJURIOUS BEHAVIOR","organSystem":"GENERAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"SUICIDAL IDEATION","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":47},{"groupId":"EG001","numAffected":1,"numAtRisk":46}]},{"term":"SUICIDE ATTEMPT","organSystem":"PSYCHIATRIC DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":47},{"groupId":"EG001","numAffected":3,"numAtRisk":46}]},{"term":"VOMITING","organSystem":"GASTROINTESTINAL DISORDERS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":47},{"groupId":"EG001","numAffected":4,"numAtRisk":46}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Samuel Wilkinson, MD, Associate Professor of Psychiatry","organization":"Yale University School of Medicine","email":"samuel.wilkinson@yale.edu","phone":"(203) 288-0414"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-11-13","uploadDate":"2026-05-20T15:58","filename":"Prot_SAP_000.pdf","size":1021995}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003863","term":"Depression"},{"id":"D013405","term":"Suicide"}],"ancestors":[{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"},{"id":"D016728","term":"Self-Injurious Behavior"}]},"interventionBrowseModule":{"meshes":[{"id":"D015928","term":"Cognitive Behavioral Therapy"}],"ancestors":[{"id":"D001521","term":"Behavior Therapy"},{"id":"D011613","term":"Psychotherapy"},{"id":"D004191","term":"Behavioral Disciplines and Activities"}]}},"hasResults":true}